Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009

Decision Resources forecasts sales of Rituxan/MabThera, Erbitux and Herceptin

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.

16 Sep 2009

MDVIP's medical director suggests preventive measures for flu

Dr. Bernard Kaminetsky, the medical director of MDVIP, a national network of affiliated primary care doctors focused on preventive care, recommends, “Talk to your primary care physician now about the flu, both seasonal and H1N1 flu. Your primary care doctor is the one who can best prepare you for the upcoming season with vaccinations as well as information specific to you.”

16 Sep 2009

Six research project grants aimed at improving human health awarded

Six research project grant awards totaling $5.1 million will be made to Washington life sciences organizations and their partners, the state’s Life Sciences Discovery Fund announced today.

16 Sep 2009

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

HUYA Bioscience International, the leader in global pharmaceutical co-development with China, today announced a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). HUYA has established a series of strategic partnerships with Chinese science institutes that affords it the opportunity to expand its portfolio of novel biopharmaceutical products.

15 Sep 2009

New data reveals the evolution of Immunoglobulin E

Immunoglobulin E (IgE) is the main actor in the drama of allergy. The biological role of IgE in the immune response of an organism and the lack of control leading to allergy is the research topic of Gernot Achatz, Molekular Biology, University of Salzburg. At the 2nd European Congress of Immunology ECI 2009 held in Berlin the scientist presents new data revealing the evolution of IgE.

15 Sep 2009

Clinical trial data of Genous Bio-engineered R stent to be presented

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

15 Sep 2009

New 'adjuvant' developed by scientists could allow the creation of important new vaccines

Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

15 Sep 2009

FDA clears Diagnostic HYBRIDS' D3 FastPoint L-DFA Respiratory Virus Identification Kit

Diagnostic HYBRIDS, a leading developer of IVD fluorescent staining kits and cell culture products, today announced the U.S. Food and Drug Administration (FDA) (510k) clearance of its D3 FastPointTM L-DFATM Respiratory Virus Identification Kit, which allows the individual detection of influenza A, influenza B, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), adenovirus and parainfluenza viruses from a patient’s specimen in under 30 minutes.

15 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.

14 Sep 2009

Early vaccination minimizes the risk of damage by potentially harmful infections

Parents should not be worried, that early vaccination would overwhelm their babies. Recent data show, that the immune system of newborns is able to respond to a world full of antigens already at birth.

14 Sep 2009

Study reveals feasibility of OrbusNeich's Genous stent in patients needing undeferrable non-cardiac surgery

OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).

14 Sep 2009

Phase IIa trial results of panobacumab released

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates.

14 Sep 2009

New method for detecting oxidative stress in tumor cells

The growth of cancerous tumors is fueled, at least in part, by the buildup of free radicals---highly reactive oxygen-containing molecules.

14 Sep 2009

Alcon to acquire ESBATech AG

Alcon (NYSE:ACL) announced today that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. Alcon will pay ESBATech shareholders $150 million in cash at closing, plus contingent payments of up to $439 million based upon the achievement of future research and development milestones that would be expected to create value for Alcon.

14 Sep 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009

Accupac to manufacture Access Pharmaceuticals' MuGard

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

11 Sep 2009